Aktienanalyse zu Vistagen Therapeutics Inc (VTGN)VTGNVistagen Therapeutics Inc

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Vistagen Therapeutics is not a good buy right now due to its current price of $0.1645, which is near its 52-week low of $0.16, and a troubling RSI of 32.407 indicating oversold conditions. The company has experienced a staggering 95.87% decline over the past year, and despite a revenue surge to $1.27 million, it reported a net loss of $13 million in the last quarter, reflecting ongoing financial struggles. The main risk is the failure of its drug trial, which caused a 71% drop in stock price, highlighting significant volatility and uncertainty.

1 analysts cover VTGN: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 0.97.